JP2016501852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501852A5 JP2016501852A5 JP2015543216A JP2015543216A JP2016501852A5 JP 2016501852 A5 JP2016501852 A5 JP 2016501852A5 JP 2015543216 A JP2015543216 A JP 2015543216A JP 2015543216 A JP2015543216 A JP 2015543216A JP 2016501852 A5 JP2016501852 A5 JP 2016501852A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cellular
- particulate
- fecal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000002550 fecal Effects 0.000 claims 10
- 230000001413 cellular Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 206010008874 Chronic fatigue syndrome Diseases 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- -1 mutacin Proteins 0.000 claims 3
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 241000193403 Clostridium Species 0.000 claims 2
- 206010009887 Colitis Diseases 0.000 claims 2
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 claims 2
- 101710034658 DNASE1 Proteins 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000007784 Diverticulitis Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010022437 Insomnia Diseases 0.000 claims 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 231100000765 Toxin Toxicity 0.000 claims 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 201000008286 diarrhea Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 244000005706 microflora Species 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 108020003112 toxins Proteins 0.000 claims 2
- 235000013619 trace mineral Nutrition 0.000 claims 2
- 241001515965 unidentified phage Species 0.000 claims 2
- HMMGKOVEOFBCAU-XTTIIYOSSA-N (3R,4R,6aR,6bS,8aR,11R,12S,12aR,14aR,14bS)-3-acetyloxy-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4a,5,6,7,8,9,10,11,12,12a,14a-tetradecahydropicene-4-carboxylic acid Chemical compound C1C[C@@H](OC(C)=O)[C@](C)(C(O)=O)C2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC(=O)[C@@H]3[C@]21C HMMGKOVEOFBCAU-XTTIIYOSSA-N 0.000 claims 1
- VOUGEZYPVGAPBB-UHFFFAOYSA-N 3-methoxy-5-methyl-4-oxohexa-2,5-dienoic acid Chemical compound OC(=O)C=C(OC)C(=O)C(C)=C VOUGEZYPVGAPBB-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 101700017503 BACT Proteins 0.000 claims 1
- 101700060967 BCN1 Proteins 0.000 claims 1
- 206010006326 Breath odour Diseases 0.000 claims 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N Cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 229940109262 Curcumin Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010016256 Fatigue Diseases 0.000 claims 1
- LAWKVNVCUPIOMG-HWWYPGLISA-N Gardimycin Chemical compound C1=CC=C2C(C[C@H](C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@H](CC)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(O)=O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](C)NC(=O)[C@@H](CC)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)N)[C@@H](C)CC)C(C)C)=CNC2=C1 LAWKVNVCUPIOMG-HWWYPGLISA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 229940047122 Interleukins Drugs 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 229940078795 Lactoferrin Drugs 0.000 claims 1
- 102000010445 Lactoferrin Human genes 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- QJDWKBINWOWJNZ-IDGBIKHQSA-N Lanthiopeptin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NC3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@@H](C(SC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CS[C@@H]3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 QJDWKBINWOWJNZ-IDGBIKHQSA-N 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 210000003097 Mucus Anatomy 0.000 claims 1
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Mycoin C Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 108010053775 Nisin Proteins 0.000 claims 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 241000233855 Orchidaceae Species 0.000 claims 1
- 206010037844 Rash Diseases 0.000 claims 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims 1
- 229940081973 S-Adenosylmethionine Drugs 0.000 claims 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine zwitterion Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims 1
- 208000002203 Sacroiliac Arthritis Diseases 0.000 claims 1
- 235000006580 Salvadora persica Nutrition 0.000 claims 1
- 240000007542 Salvadora persica Species 0.000 claims 1
- 102400000830 Saposin-B Human genes 0.000 claims 1
- 101800001697 Saposin-B Proteins 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N Subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 229940029983 VITAMINS Drugs 0.000 claims 1
- 231100000611 Venom Toxicity 0.000 claims 1
- 210000001048 Venoms Anatomy 0.000 claims 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 Xylitol Drugs 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 229960001570 ademetionine Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000844 anti-bacterial Effects 0.000 claims 1
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 201000002055 autistic disease Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 108010063293 cinnamycin Proteins 0.000 claims 1
- 101710036704 comC1 Proteins 0.000 claims 1
- 101710036700 comC2 Proteins 0.000 claims 1
- 101700022893 csp Proteins 0.000 claims 1
- 101700028030 csp-3 Proteins 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 230000003111 delayed Effects 0.000 claims 1
- 150000002066 eicosanoids Chemical class 0.000 claims 1
- 108010064962 epidermin Proteins 0.000 claims 1
- CXTXHTVXPMOOSW-JUEJINBGSA-N epidermin Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@H](C(N\C=C/SC2)=O)CSC1)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 CXTXHTVXPMOOSW-JUEJINBGSA-N 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 108010070411 gardimycin Proteins 0.000 claims 1
- 201000011200 hepatorenal syndrome Diseases 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000000968 intestinal Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 108010067215 mersacidin Proteins 0.000 claims 1
- JSWKNDSDVHJUKY-CYGWNLPQSA-N mersacidin Chemical compound C([C@@H](C(=O)N[C@@H]1[C@H](C)SC[C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H]1[C@H](C)SC[C@H]2C(=O)N[C@H](C(N/C=C/S[C@@H](C)C(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)[C@H](C)CC)NC(=O)[C@H]1[C@@H](SC[C@H](N)C(=O)N1)C)C1=CC=CC=C1 JSWKNDSDVHJUKY-CYGWNLPQSA-N 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 108010079904 microcin Proteins 0.000 claims 1
- 239000011785 micronutrient Substances 0.000 claims 1
- 235000013369 micronutrients Nutrition 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 201000008895 mood disease Diseases 0.000 claims 1
- 201000003346 myoclonic dystonia Diseases 0.000 claims 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 claims 1
- 201000008709 myotonic dystrophy type 2 Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 239000004309 nisin Substances 0.000 claims 1
- 235000010297 nisin Nutrition 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000018612 quorum sensing Effects 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 108010082567 subtilin Proteins 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 108010067167 thuricin Proteins 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 239000002435 venom Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
Claims (15)
- 精製された糞便微生物叢および1つまたは複数の非-細胞性であって非-粒子状の糞便成分の組合せから必須になる再構成された糞便フローラを含む、医薬組成物。
- 1つまたは複数の非-細胞性であって非-粒子状の糞便成分が追加された、精製された糞便微生物叢を含む、医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、合成分子、糞便微生物によって産生される生物学的に活性な分子、またはこれら両方を含む、請求項1または2に記載の医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、生物学的に活性なタンパク質もしくはペプチド、微量栄養素、脂質、糖、低分子の炭水化物、微量元素、無機塩、灰分、粘液、アミノ酸、栄養素、ビタミン、ミネラルまたはそれらの任意の組合せを含む、請求項1または2に記載の医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、バクテリオシン、ランバイオティクスおよびラクチシンからなる群から選択される1つまたは複数の生物学的に活性な分子を含む、請求項1または2に記載の医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、コリシン、トロウドゥリキシン、プタインディシン、ミクロシンおよびサブチロシンAからなる群から選択される1つまたは複数のバクテリオシンを含む、請求項1または2に記載の医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、ツリシン、ナイシン、スブチリン、エピデルミン、ミュータシン、メルサシジン、アクタガルジンおよびシンナマイシンからなる群から選択される1つまたは複数のランバイオティクスを含む、請求項1または2に記載の医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、抗-胞子化合物、抗菌化合物、抗-炎症性化合物、またはそれらの任意の組合せを含む、請求項1または2に記載の医薬組成物。
- 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、インターロイキン、サイトカイン、ロイコトリエン、エイコサノイド、またはそれらの任意の組合せを含む、請求項1または2に記載の医薬組成物。
- 前記精製された糞便微生物叢が、約0.1mmより大きなサイズを有する粒子を含まない、請求項1または2に記載の医薬組成物。
- バイオフィルム崩壊剤を更に含むか、またはバイオフィルム崩壊剤と併せて使用される、請求項1または2に記載の医薬組成物。
- 前記バイオフィルム崩壊剤が、デオキシリボヌクレアーゼ(DNアーゼ)、N-アセチルシステイン、アルギン酸リアーゼ、グリコシドヒドロラーゼディスパーシンB、クオラムセンシング阻害剤、リボ核酸III阻害ペプチド、サルバドラ・ペルシカ抽出物、コンピテンス刺激ペプチド、パツリン、ペニシリン酸、カテリシジン由来ペプチド、小溶解性ペプチド、PTP-7、酸化窒素、ネオエマルジョン、オゾン、溶解性バクテリオファージ、ラクトフェリン、キシリトールヒドロゲル、合成鉄キレート剤、クルクミン、銀ナノ粒子、アセチル-11-ケト-β-ボスウェル酸(AKBA)、シネファンギン、S-アデノシルメチオニン、S-アデノシル-ホモシステイン、デリシアフラノン、およびN-スルホニルホモセリンラクトンからなる群から選択される、1つまたは複数の酵素を含む、請求項11に記載の医薬組成物。
- 遅延性または徐放性の腸溶性放出用に配合された、請求項1または2に記載の医薬組成物。
- 必要とする対象における、腸管機能不全成分を有する状態の治療または予防のための、請求項1から13のいずれか一項に記載の医薬組成物。
- 前記状態が、便秘、腹痛、下痢、クローン病、毒、毒素、感染、毒素媒介性旅行者下痢症、クロストリジウム、C.パーフリンジェンス・ウェルチ、C.ディフィシル感染、またはクロストリジウム感染に関連した偽膜性大腸炎、脊椎関節症、脊椎関節炎、仙腸関節炎、腎炎症候群、炎症性状態、自己免疫状態、ループス、過敏性腸症候群(IBS)、結腸炎、潰瘍性結腸炎、自閉症、神経変性疾患、筋委縮性側索硬化症(ALS)、多発性硬化症(MS)、パーキンソン病(PD)、ミオクローヌスジストニア、シュタイネルト病、近位型筋強直性ミオパシー、関節リウマチ(RA)、若年性特発性関節炎(HA)、慢性疲労症候群、良性筋痛性脳脊髄炎、慢性疲労免疫機能障害症候群、慢性感染性単核球症、流行性筋痛性脳脊髄炎、肥満、低血糖症、前糖尿病性症候群、I型糖尿病、II型糖尿病、特発性血小板減少性紫斑病(ITP)、急性または慢性アレルギー反応、蕁麻疹、発疹、皮膚掻痒、慢性皮膚掻痒、不眠症、慢性不眠症、けいれん大発作、けいれん小発作、口臭、肝腎症候群、憩室炎、再発性憩室炎、アトピー性状態、喘息、注意欠陥障害(ADD)、強迫性障害(OCD)、鬱病、統合失調症および気分障害からなる群から選択される、請求項14に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729994P | 2012-11-26 | 2012-11-26 | |
US61/729,994 | 2012-11-26 | ||
PCT/AU2013/001362 WO2014078911A1 (en) | 2012-11-26 | 2013-11-26 | Compositions for the restoration of a fecal microbiota and methods for making and using them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016501852A JP2016501852A (ja) | 2016-01-21 |
JP2016501852A5 true JP2016501852A5 (ja) | 2017-05-18 |
Family
ID=50775319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015543216A Pending JP2016501852A (ja) | 2012-11-26 | 2013-11-26 | 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150297642A1 (ja) |
EP (1) | EP2922555A4 (ja) |
JP (1) | JP2016501852A (ja) |
KR (1) | KR20150103012A (ja) |
CN (1) | CN104918624A (ja) |
AU (2) | AU2013350328A1 (ja) |
BR (1) | BR112015012123A8 (ja) |
CA (1) | CA2896795A1 (ja) |
IL (1) | IL238993A0 (ja) |
WO (1) | WO2014078911A1 (ja) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
WO2008143889A1 (en) | 2007-05-14 | 2008-11-27 | Research Foundation Of State University Of New York | Induction of a physiological dispersion response in bacterial cells in a biofilm |
US9629881B2 (en) | 2010-02-01 | 2017-04-25 | Rebiotix, Inc. | Bacteriotherapy for clostridium difficile colitis |
WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性t細胞の増殖または集積を誘導する作用を有する組成物 |
US9308226B2 (en) | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
EP2785828B1 (en) * | 2011-12-01 | 2020-04-08 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
KR102099503B1 (ko) | 2013-06-05 | 2020-04-09 | 리바이오틱스, 인코퍼레이티드 | 미생물상 복원 요법(mrt) 조성물 |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
GB2529893A (en) * | 2014-09-08 | 2016-03-09 | Geotechniquesres Ltd | Apparatus and method for separating pollen and optionally microbiota from honey |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
KR20220151045A (ko) | 2014-12-23 | 2022-11-11 | 4디 파마 리서치 리미티드 | 면역 조정 |
SE1550189A1 (en) * | 2015-02-19 | 2016-08-20 | Achim Biotherapeutics Ab | Therapeutic and prophylactic composition produced by microbiota |
WO2016172380A1 (en) * | 2015-04-21 | 2016-10-27 | Epibiome, Inc. | Compositions and methods for increasing the susceptibility of bacteria to antibiotics |
US12050161B2 (en) | 2015-04-24 | 2024-07-30 | Maat Pharma | Microorganism sampling method, microorganism sampling device and sampling kit comprising such a sampling device |
FR3035328B1 (fr) | 2015-04-24 | 2019-08-23 | Maat Pharma | Procede de preparation d'un echantillon de microbiote fecal |
FR3035317B1 (fr) | 2015-04-24 | 2019-06-14 | Maat Pharma | Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif |
WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
CN114159476A (zh) | 2015-05-14 | 2022-03-11 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
NZ776366A (en) * | 2015-05-22 | 2023-02-24 | Univ Minnesota | Methods for treating autism spectrum disorder and associated symptoms |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10226431B2 (en) | 2015-06-09 | 2019-03-12 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
PT3240554T (pt) | 2015-06-15 | 2019-11-04 | 4D Pharma Res Ltd | Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
JP6426264B2 (ja) | 2015-06-15 | 2018-11-21 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
JP6439037B2 (ja) | 2015-06-15 | 2018-12-19 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
CN105193856A (zh) * | 2015-09-25 | 2015-12-30 | 南昌大学 | 一种人工培养粪便菌群移植在肠道疾病治疗中的应用 |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CN112569262A (zh) | 2015-11-20 | 2021-03-30 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CN106811425B (zh) * | 2015-11-27 | 2020-10-09 | 重庆北芝堂生物科技有限公司 | 一种从人体粪便中分离肠道菌群的方法 |
FR3045383B1 (fr) | 2015-12-18 | 2019-06-14 | Maat Pharma | Procede de lyophilisation d'un echantillon de microbiote fecal |
EP3520801A1 (en) | 2016-03-04 | 2019-08-07 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
SG11201807811RA (en) * | 2016-03-11 | 2018-10-30 | Evolve Biosystems Inc | Food compositions for weaning |
WO2017203533A1 (en) * | 2016-05-25 | 2017-11-30 | Mybiotics Pharma Ltd. | Composition and methods for microbiota therapy |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
US20180030403A1 (en) | 2016-07-28 | 2018-02-01 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
US20180036352A1 (en) * | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US20180185421A1 (en) * | 2016-08-29 | 2018-07-05 | Tokyo Metropolitan Government | Composition comprising fecal microbiota |
AU2017327369A1 (en) | 2016-09-13 | 2019-05-02 | Allergan, Inc. | Stabilized non-protein Clostridial toxin compositions |
WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
WO2018071532A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating chronic fatigue syndrome and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
WO2018071534A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating irritable bowel syndrome and related disorders |
WO2018081196A1 (en) * | 2016-10-31 | 2018-05-03 | Kimberly-Clark Worldwide, Inc. | Method for archiving a microbiome |
IT201600122310A1 (it) | 2016-12-01 | 2018-06-01 | Sofar Spa | Composizione per uso nella terapia di alterazioni dell'intestino |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
FR3062063B1 (fr) * | 2017-01-26 | 2019-04-19 | Centre National De La Recherche Scientifique | Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
CN110831606A (zh) | 2017-04-05 | 2020-02-21 | 克雷斯顿沃控股公司 | 治疗帕金森氏病(pd)和相关疾病的组合物和方法 |
CN107126445A (zh) * | 2017-04-20 | 2017-09-05 | 江南大学 | 粪菌移植在治疗帕金森病方面的应用 |
DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
CN108947097B (zh) * | 2017-05-27 | 2021-10-22 | 宝山钢铁股份有限公司 | 一种平整液废水臭氧生化耦合的处理方法和装置 |
PT3600364T (pt) | 2017-06-14 | 2020-10-19 | 4D Pharma Res Ltd | Composições compreendendo uma estirpe bacteriana do género megasphera e suas utilizações |
SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
AU2018253466B2 (en) * | 2017-07-17 | 2019-03-28 | smartDNA Pty Ltd | Method of diagnosing a dysbiosis |
JP2020530494A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド. | 健康な腸バリアを維持及び回復するための組成物及び方法 |
EP3485879A1 (en) * | 2017-11-17 | 2019-05-22 | Maat Pharma | Pharmaceutical oral formulation comrpsing bacteria |
CN112203669A (zh) | 2018-02-23 | 2021-01-08 | 克雷斯顿沃控股公司 | 微生物组相关的免疫疗法 |
WO2019213595A1 (en) * | 2018-05-04 | 2019-11-07 | Ferring B.V. | Microbiota restoration therapy (mrt) compositions and methods of manufacture |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
US11859214B1 (en) | 2018-08-17 | 2024-01-02 | The Government Of The United States, As Represented By The Secretary Of The Army | Automated system for simulating the human lower gastrointestinal tract |
CN109010380A (zh) * | 2018-08-21 | 2018-12-18 | 卓源健康科技有限公司 | 一种粪菌移植临床治疗中的肠道菌群制剂的工艺 |
WO2020069280A1 (en) | 2018-09-27 | 2020-04-02 | Crestovo Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
WO2020086413A1 (en) * | 2018-10-26 | 2020-04-30 | Locus Oil Ip Company, Llc | Personalized system for restoring the gastrointestinal tract microbiome |
CA3116775A1 (en) * | 2018-11-09 | 2020-05-14 | The Brigham And Women's Hospital, Inc. | Therapeutic microbiota for the treatment and/or prevention of dysbiosis |
US11058634B2 (en) | 2018-11-19 | 2021-07-13 | Steven J. Edwards | Adherent oral pharmabiotic delivery strip |
KR20220000398A (ko) | 2019-04-12 | 2022-01-03 | 로커스 아이피 컴퍼니 엘엘씨 | 향상된 탄소 격리 및 가축 생산 온실 가스 배출 감소를 위한 목초지 처리 |
WO2020237323A1 (en) * | 2019-05-31 | 2020-12-03 | Borody Thomas J | Devices, compositions and methods for colonic microbiome engraftment |
US12053447B2 (en) | 2019-06-25 | 2024-08-06 | NuBioPharma, LLC | Oral solution and powder to liquid compositions of balsalazide |
EP3996727A4 (en) * | 2019-07-11 | 2023-03-15 | Milis, Antony | PROCEDURE FOR PREPARING INTESTINAL MUCOA FOR IMPROVING MICROBIAL COLONIZATION |
WO2021016081A1 (en) | 2019-07-19 | 2021-01-28 | Finch Therapeutics Holdings Llc. | Methods and products for treatment of gastrointestinal disorders |
EP4007540A4 (en) * | 2019-08-02 | 2023-08-16 | Thomas Julius Borody | COLON TREATMENT METHODS AND APPARATUS |
US20220322707A1 (en) * | 2019-08-14 | 2022-10-13 | Locus Ip Company, Llc | Drinkable Supplement Composition for Improved Health and Hydration |
JP2022547330A (ja) | 2019-09-13 | 2022-11-11 | フィンチ セラピューティクス ホールディングス エルエルシー | 自閉症スペクトラム障害を治療するための組成物および方法 |
JP2022552005A (ja) | 2019-10-18 | 2022-12-14 | フィンチ セラピューティクス ホールディングス エルエルシー | 細菌代謝産物を対象に送達するための組成物および方法 |
WO2021097288A1 (en) | 2019-11-15 | 2021-05-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating neurodegenerative diseases |
EP4085916A4 (en) | 2019-11-26 | 2024-03-27 | Tokyo Metropolitan Hospital Organization | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR GRAFT VERSUS HOST DISEASE |
WO2021115415A1 (en) * | 2019-12-11 | 2021-06-17 | Microbiota I - Center (Magic) Limited | Methods for treating bacterial infections |
WO2021142347A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for non-alcoholic steatohepatitis (nash) |
WO2021142353A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv) |
WO2021142358A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatic encephalopathy (he) |
CN111249314B (zh) * | 2020-03-03 | 2022-03-29 | 深圳未知君生物科技有限公司 | 人体共生菌群在提高肿瘤免疫治疗应答中的作用 |
EP4125440A1 (en) * | 2020-03-31 | 2023-02-08 | Biomuse Ltd. | Bacteria for the prevention and treatment of smoke-induced lung damage |
WO2021202806A1 (en) | 2020-03-31 | 2021-10-07 | Finch Therapeutics Holdings Llc | Compositions comprising non-viable fecal microbiota and methods of use thereof |
CN111544550B (zh) * | 2020-06-19 | 2021-11-09 | 南京法迈特科技发展有限公司 | 中药配方菌群胶囊及制备方法和在制备治疗2型糖尿病的药物中的应用 |
WO2022178294A1 (en) | 2021-02-19 | 2022-08-25 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
EP4098268A1 (en) * | 2021-06-01 | 2022-12-07 | Lietuvos Sveikatos Mokslu Universitetas | Modification of fecal microbiota with capsules containing lyophilized fecal matter filtrate |
ES2933976B2 (es) * | 2021-08-11 | 2024-05-08 | Fundacio Inst Dinvestigacio Biomedica De Girona Dr Josep Trueta Idibgi | Bacteriofago para uso terapeutico |
CN114027479A (zh) * | 2021-11-18 | 2022-02-11 | 武汉自然萃创新科技有限公司 | 一种微胶囊化益生菌蜂蜜的制备方法 |
EP4183403A1 (en) * | 2021-11-19 | 2023-05-24 | Lietuvos Sveikatos Mokslu Universitetas | Modification of fecal microbiota with capsules containing gram-positive bacteria |
CN114350520A (zh) * | 2022-01-19 | 2022-04-15 | 厦门承葛生物科技有限公司 | 一种肠道菌群的过滤提取方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040170617A1 (en) * | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
CN1737108A (zh) * | 2004-08-18 | 2006-02-22 | 王健 | 一种从人体排泄物中分离益生菌的方法 |
US9320795B2 (en) * | 2007-12-13 | 2016-04-26 | Zoctis Server LLC | Bacteriophage preparations and methods of use thereof |
GB0916335D0 (en) * | 2009-09-17 | 2009-10-28 | Martin W J | Medicaments |
US9308226B2 (en) * | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9968638B2 (en) * | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
CA2848757C (en) * | 2011-09-14 | 2021-11-09 | University Of Guelph | Methods to culture human gastrointestinal microorganisms |
WO2013090825A1 (en) * | 2011-12-15 | 2013-06-20 | Pureflora, Inc. | Device for the collection, refinement, and administration of gastrointestinal microflora |
-
2013
- 2013-11-26 JP JP2015543216A patent/JP2016501852A/ja active Pending
- 2013-11-26 KR KR1020157017274A patent/KR20150103012A/ko not_active Application Discontinuation
- 2013-11-26 AU AU2013350328A patent/AU2013350328A1/en not_active Abandoned
- 2013-11-26 CA CA2896795A patent/CA2896795A1/en not_active Abandoned
- 2013-11-26 US US14/647,062 patent/US20150297642A1/en not_active Abandoned
- 2013-11-26 EP EP13857085.8A patent/EP2922555A4/en not_active Ceased
- 2013-11-26 CN CN201380070276.0A patent/CN104918624A/zh active Pending
- 2013-11-26 BR BR112015012123A patent/BR112015012123A8/pt not_active IP Right Cessation
- 2013-11-26 WO PCT/AU2013/001362 patent/WO2014078911A1/en active Application Filing
-
2015
- 2015-05-25 IL IL238993A patent/IL238993A0/en unknown
-
2017
- 2017-06-02 US US15/612,459 patent/US20180177831A9/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201590A patent/AU2018201590A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016501852A5 (ja) | ||
Allain et al. | Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota | |
Meade et al. | Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile? | |
Ilinskaya et al. | Secretome of intestinal Bacilli: a natural guard against pathologies | |
Leshem et al. | Immune-microbiota interplay and colonization resistance in infection | |
Pace et al. | Probiotics in digestive diseases: focus on Lactobacillus GG. | |
Yang et al. | Bile acid–gut microbiota axis in inflammatory bowel disease: from bench to bedside | |
Rea et al. | Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection | |
Singh et al. | Identification, purification and characterization of laterosporulin, a novel bacteriocin produced by Brevibacillus sp. strain GI-9 | |
Saraoui et al. | Inhibition mechanism of Listeria monocytogenes by a bioprotective bacteria Lactococcus piscium CNCM I-4031 | |
Li et al. | Antimicrobial resistance of Campylobacter species isolated from broilers in live bird markets in Shanghai, China | |
Patenge et al. | Inhibition of growth and gene expression by PNA-peptide conjugates in Streptococcus pyogenes | |
Yang et al. | Non-antibiotic therapy for Clostridioides difficile infection: A review | |
Egan et al. | Bacteriocins: antibiotics in the age of the microbiome | |
Xu et al. | Isolation and characterization of cyclic lipopeptides with broad-spectrum antimicrobial activity from Bacillus siamensis JFL15 | |
BRPI1011277B8 (pt) | produto de bacteriocina lactobacillus pentosus, alimento e composições farmacêuticas contendo o mesmo e uso do mesmo | |
Kuniyoshi et al. | An oxidation resistant pediocin PA-1 derivative and penocin A display effective anti-Listeria activity in a model human gut environment | |
Mukherjee et al. | Bacteriocin-producing strains of Lactobacillus plantarum inhibit adhesion of Staphylococcus aureus to extracellular matrix: quantitative insight and implications in antibacterial therapy | |
Cirkovic et al. | Licheniocin 50.2 and bacteriocins from Lactococcus lactis subsp. lactis biovar. diacetylactis BGBU1-4 inhibit biofilms of coagulase negative Staphylococci and Listeria monocytogenes clinical isolates | |
Dare et al. | LysPGS formation in Listeria monocytogenes has broad roles in maintaining membrane integrity beyond antimicrobial peptide resistance | |
Pantic et al. | Effects of tigerinin peptides on cytokine production by mouse peritoneal macrophages and spleen cells and by human peripheral blood mononuclear cells | |
Burkovski | Corynebacterium pseudodiphtheriticum: Putative probiotic, opportunistic infector, emerging pathogen | |
Yu et al. | Biosynthetic microcin J25 exerts strong antibacterial, anti-inflammatory activities, low cytotoxicity without increasing drug-resistance to bacteria target | |
Sivaraj et al. | Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy | |
Yang et al. | Screening, probiotic properties, and inhibition mechanism of a Lactobacillus antagonistic to Listeria monocytogenes |